Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

ate-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.  Afatinib is an investigational orally-administered irreversible inhibitor of the ErbB family of receptor tyrosine kinases, which is currently in phase III clinical development in advanced NSCLC, head and neck cancer, and breast cancer.  Boehringer Ingelheim recently submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of afatinib as a treatment for patients with EGFR (ErbB1) mutation-positive NSCLC.  The company is working on applications for afatinib in a number of countries, including the United States.  Nintedanib (BIBF 1120) is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis and is currently in Phase III clinical development in NSCLC and ovarian cancer.  Volasertib is an investigational inhibitor of polo-like kinase that is currently being investigated in early phase trials.  Boehringer Ingelheim's oncology pipeline continues to evolve and demonstrates the company's continued commitment to the disease area.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110.  Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
... ... Presence in China, CAMBRIDGE, Mass., April 22 ... a major new research and,development center in Beijing. The initiative is ... a,long-term presence in China., The new facility will be used ...
... to Threat of Bioterrorism, Says UK Board ... Member General Lord Guthrie, ... to develop and deploy technology that can neutralize and destroy,a biohazardous ... has partnered with General Lord Guthrie,former chief of the British Defense ...
... April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,(,Lorus,), ... and,development of pharmaceutical products and technologies for ... of a development program aimed at,expanding the ... for the treatment of superficial bladder cancer., ...
Cached Biology Technology:Genzyme to Build New R&D Center in Beijing 2Genzyme to Build New R&D Center in Beijing 3Genzyme to Build New R&D Center in Beijing 4Genzyme to Build New R&D Center in Beijing 5Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 2Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 3Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4
(Date:7/10/2014)... of enzymes known as heme enzymes, due to the ... At the centre of the heme cofactor is an ... reacting heme is in an intermediate state called Compound ... is whether this oxidation involves just an oxygen atom ... question has implications for understanding oxidative processes within living ...
(Date:7/10/2014)... (ACS) announced today that Courtney Aldrich, Ph.D., will ... Diseases as editor-in-chief. With the first issue ... journal will meet a growing demand for a ... , "Our vision is to develop a journal ... the basic science that advances the field and ...
(Date:7/10/2014)... from The University of Texas Health Science Center at ... (IYG), a health education program designed to delay sexual ... dating violence behaviors among minority youth. , According to ... of high school youth are victims of physical dating ... percent are victims of emotional dating violence. Previous studies ...
Breaking Biology News(10 mins):Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2
... NEW YORK, February 4, 2011 A defining feature ... today,s age of computational science, this means higher standards ... that generated the results along with the published research ... widely accessible, facilitating re-use and verification of results. ...
... the annual meeting of the American Association for the Advancement ... climate change could increase exposure and risk of human illness ... studies projecting impacts to be felt within 30 years. ... warmest for sea surface temperatures, NOAA and our partners are ...
... Among the many differences between girls and boys, add the ... the list. , Results of a double-blind, placebo-controlled, dose-response study ... general, boys get a greater rush and more energy from ... caffeine had a positive effect on their athletic performance. Girls ...
Cached Biology News:AAAS Symposium: New research facilitates scientific knowledge transfer 2Climate projections show human health impacts possible within 30 years 2Climate projections show human health impacts possible within 30 years 3Climate projections show human health impacts possible within 30 years 4High-caffeine-consuming boys get greater rush from caffeine than girls 2High-caffeine-consuming boys get greater rush from caffeine than girls 3
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: